Chūō

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia3 trials
• Myeloproliferative neoplasms2 trials
• Polymyalgia rheumatica2 trials
• Childhood cancers1 trial
• Giant cell arteritis1 trial
• Neuroendocrine tumours1 trial

Phase

• Phase 35 trials
• Phase 11 trial

Status

• Completed4 trials
• Active, not recruiting3 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals8 trials

Running trials

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

  NCT07340138· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

  NCT06331312· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

  NCT04971226· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myeloproliferative neoplasms1 recruiting

Closed trials

• Completed

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

  NCT05767034· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Special Drug Use-results Surveillance of Scemblix Tablets

  NCT05421091· Novartis Pharmaceuticals· Source

• Completed

  LUTATHERA Injection General Use Result Survey

  NCT05844332· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

  NCT03106779· Phase 3· Novartis Pharmaceuticals· Source